55results about How to "Genetic diagnosis specific" patented technology

The invention discloses a diagnosis and treatment target TULP2 gene of a degenerative disc disease. Whether a subject has the degenerative disc disease or not can be judged or whether the subject has the risk of the degenerative disc disease or not can be diagnosed by detecting the content of TULP 2 gene and an expression product thereof in intervertebral disc tissues of the subject. In addition, the TULP2 gene is proved to be used as a drug target for treating the degenerative disc disease by researching growth, senility and apoptosis indexes of the in-vitro cultured nucleus pulposus cells.

The invention discloses a diagnostic tool for the Parkinson's disease. The diagnostic tool is used for realizing a diagnostic purpose through detecting an NACC2 gene and an expression product thereofin blood. Proven by the search of the diagnostic tool, in comparison with a normal person, the expression level of mRNA (messenger Ribonucleic Acid) of the NACC2 gene in the blood of a patient suffered from the Parkinson's disease is obviously raised. According to the relevance existing between the NACC2 gene and the Parkinson's disease, a kit for diagnosing the Parkinson's disease can be prepared, and the kit can be clinically widely applied.

The invention discloses a molecular marker for diagnosis and treatment of osteoporosis, wherein the marker for diagnosis and treatment of osteoporosis is KPNA3 gene and expression products thereof. The high-throughput sequencing and QPCR method show that the KPNA3 gene and expression products thereof have differences in expression in bone tissues between normal people and patients with osteoporosis, and according to the correlation between the expression differences, the KPNA3 gene and expression products thereof can be used for serving as the molecular marker for diagnosis and treatment of osteoporosis. In addition, in vivo experiments show that over-expression of the KPNA3 gene can promote the proliferation of bone cells, therefore the KPNA3 gene and the expression products thereof can also be used for development of drugs for treating osteoporosis.

The invention discloses a gene marker. The gene marker VSIG10L can be used for judging whether metastasis of lung squamous carcinoma occurs or not or pre-judging lung squamous carcinoma metastasis risks. The gene marker VSIG10L further can be used for preparing medicines for inhibiting or preventing lung squamous carcinoma metastasis. The gene marker has the advantages that novel diagnosis methods can be provided for clinically diagnosing lung squamous carcinoma metastasis at molecular level, and novel medicine targets can be provided for gene therapy on lung squamous carcinoma metastasis.

The invention discloses that the SENP3 gene and its expression product can be used as molecular markers for the diagnosis and treatment of esophageal cancer. By detecting the content of the SENP3 gene and its expression products in tissues, it can be determined whether the subject has esophageal cancer or whether the subject has the risk of esophageal cancer. The present invention finds that the expression inhibition of SENP3 gene can inhibit the proliferation of esophageal cancer cells by studying the proliferation of esophageal cancer cells cultured in vitro, and can also inhibit the proliferation of esophageal cancer cells by inhibiting the function of SENP3 protein. The above research results show that SENP3 gene and its The expressed product is a potential drug target for the treatment of esophageal cancer.